Looking for a Treatment for the Early Stage of Alzheimer’s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin
Background: At the earliest stage of Alzheimer’s disease (AD), although patients are still asymptomatic, cerebral alterations have already been triggered. In addition to beta amyloid (Aβ) accumulation, both glial alterations and neuroinflammation have been documented at this stage. Starting treatmen...
Main Authors: | Roberta Facchinetti, Marta Valenza, Maria Rosanna Bronzuoli, Giorgia Menegoni, Patrizia Ratano, Luca Steardo, Patrizia Campolongo, Caterina Scuderi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/11/3802 |
Similar Items
-
Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor-α in an In Vitro Model of Alzheimer’s Disease
by: Roberta Facchinetti, et al.
Published: (2022-05-01) -
Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications
by: Marta Valenza, et al.
Published: (2022-08-01) -
Alternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes
by: Marta Valenza, et al.
Published: (2021-04-01) -
Co-ultramicronized palmitoylethanolamide/luteolin promotes neuronal regeneration after spinal cord injury
by: Rosalia eCrupi, et al.
Published: (2016-03-01) -
Targeting neuroinflammation in Alzheimer’s disease
by: Bronzuoli MR, et al.
Published: (2016-11-01)